Citius Pharmaceuticals to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
CRANFORD, N.J., Oct. 25, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, announced today that its Executive Chairman, Leonard Mazur, will present at the Dawson James 2018 Small Cap Growth Stock Conference. The Conference will be held on October 30, 2018 at the Wyndham Grand Hotel in Jupiter, Florida.
Event: Dawson James 2018 Small Cap Growth Stock Conference
Location: Wyndham Grand Hotel, Jupiter, Florida
Date: October 30, 2018
During the conference, Executive Chairman, Mr. Leonard Mazur will deliver the Company's corporate presentation and discuss recent business highlights. Management will also be available for one-on-one meetings. To arrange a meeting with management, please contact Mr. Andrew Scott: firstname.lastname@example.org.
About Dawson James, Inc.
Dawson James Securities, a member of FINRA/SIPC, is a full-service investment bank headquartered in Boca Raton, FL. The company has set out to create the highest-quality, full service investment firm specializing in the complex and fast-moving healthcare, biotechnology, technology and clean-tech sectors. For more information, please visit; http://www.dawsonjames.com.
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously-approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs; by using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, please visit www.citiuspharma.com
Vice President, Corporate Development
SOURCE Citius Pharmaceuticals, Inc.
Released October 25, 2018